We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Overtesting for Diabetes Tends to Reap Negative “Rewards”

By LabMedica International staff writers
Posted on 23 Dec 2015
Researchers report a US national trend toward overtesting of glycated hemoglobin (HbA1c) levels in adult patients with Type 2 diabetes, leading to unnecessary cost, time, and other burdens for patients and providers, as well as potential patient health complications due to overtreatment with hypoglycemic drugs.

A new study led by Mayo Clinic (Rochester, MN, USA) researchers has shown that patients with Type 2 diabetes are often tested much more frequently than clinically indicated. More...
Type 2 diabetes monitoring and treatment protocols are not well defined by professional societies and regulatory bodies. While lower thresholds of testing frequencies are often discussed, the upper boundaries are rarely mentioned. Yet, most agree that checking 1–2 times/year should suffice for adult patients who are not using insulin, have stable glycemic control within the recommended targets, and have no history of severe hypoglycemia or hyperglycemia. Yet, in practice, there is a much higher prevalence of excessive testing.

Upon examining a national cohort of 31,545 non-pregnant adults with controlled non-insulin-treated Type 2 diabetes, the investigators said the study provides definitive evidence of such excess testing. The patient cohort examined was derived from the OptumLabs Data Warehouse (OLDW) using de-identified administrative, pharmacy, and laboratory data from 2001 to 2011. Approximately 55% achieved and maintained the recommended less than 7% HbA1c level and were tested 3–4 times/year; 6% were tested 5 or more times.

“Our findings are concerning, especially as we focus more on improving the value of care we deliver to our patients—not only ensuring maximal benefit, but also being mindful of waste, patient burden, and healthcare costs,” said study lead investigator Rozalina McCoy, MD, Mayo Clinic, “As providers, we must be ever vigilant.”

“Potential reasons for more frequent testing include clinical uncertainty; misunderstanding of the nature of the test—that is, not realizing that HbA1c represents a 3-month average of glycemic control; or a desire for diagnostic and management thoroughness,” said Dr. McCoy, “Other times, it may be the result of fragmentation of care (more than one unconnected provider); the need to fulfill regulatory demands, such as public reporting of performance metrics; or internal tracking of performance. “Because our culture often thinks that more is better” patients and providers may favor additional testing due to a desire for comprehensive care, she added.

The researchers also found that excessive testing increased the odds of overtreatment with one or more drugs, despite normal HbA1c levels, and that rates of overtesting were lower among patients receiving bundled testing (i.e., cholesterol, creatinine, and HbA1c tests in the same day).

“We hope that these findings will help inform decision-making,” said Dr. McCoy.

The study was published December 8, 2015, in the British Journal of Medicine.

Related Links:

Mayo Clinic
Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
OptumLabs 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.